US Senate passes cannabis research bill, but House must weigh in
Industrial Hemp NewsMarijuana Laws, Regulations, & Politics March 2, 2023 MJ Shareholders 0
The U.S. Senate gave unanimous approval to a bipartisan bill to “cut the red tape” that stalls scientific research into the medical properties of cannabis and cannabidiols.
According to a news release issued Thursday by U.S. Sen. Dianne Feinstein, a California Democrat, the Senate approved S. 253 on a voice vote.
The measure – which would authorize the U.S. Food and Drug Administration to study cannabis products – now heads to the U.S. House of Representatives for consideration.
The bill was co-sponsored by Iowa Republican Sen. Chuck Grassley and Hawaii Democrat Brian Schatz, who both lauded the bill’s success.
“This bipartisan bill … will empower the FDA to analyze CBD and medical marijuana products in a safe and responsible way so that the American public can decide whether to utilize them in the future based on sound scientific data.”
The Senate measure comes almost a year after the U.S. Drug Enforcement Administration signaled it might ease its restrictions on marijuana research.
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
No comments so far.
Be first to leave comment below.